A naturally occurring variant of the human prion protein completely prevents prion disease

Mammalian prions, transmissible agents causing lethal neurodegenerative diseases, are composed of assemblies of misfolded cellular prion protein (PrP). A novel PrP variant, G127V, was under positive evolutionary selection during the epidemic of kuru—an acquired prion disease epidemic of the Fore population in Papua New Guinea—and appeared to provide strong protection against disease in the heterozygous state. Here we have investigated the protective role of this variant and its interaction with the common, worldwide M129V PrP polymorphism. V127 was seen exclusively on a M129 PRNP allele. We demonstrate that transgenic mice expressing both variant and wild-type human PrP are completely resistant to both kuru and classical Creutzfeldt–Jakob disease (CJD) prions (which are closely similar) but can be infected with variant CJD prions, a human prion strain resulting from exposure to bovine spongiform encephalopathy prions to which the Fore were not exposed. Notably, mice expressing only PrP V127 were completely resistant to all prion strains, demonstrating a different molecular mechanism to M129V, which provides its relative protection against classical CJD and kuru in the heterozygous state. Indeed, this single amino acid substitution (G→V) at a residue invariant in vertebrate evolution is as protective as deletion of the protein. Further study in transgenic mice expressing different ratios of variant and wild-type PrP indicates that not only is PrP V127 completely refractory to prion conversion but acts as a potent dose-dependent inhibitor of wild-type prion propagation.

[1]  J. Ironside,et al.  Variant Creutzfeldt-Jakob disease. , 2004, Folia neuropathologica.

[2]  M. Alpers.  The epidemiology of kuru: monitoring the epidemic from its peak to its end , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[3]  Michael P H Stumpf,et al.  Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics , 2003, Science.

[4]  J. Collinge,et al.  Pathogenic human prion protein rescues PrP null phenotype in transgenic mice , 2004, Neuroscience Letters.

[5]  J. Collinge,et al.  Molecular diagnosis of human prion disease. , 2008, Methods in molecular biology.

[6]  J. Collinge.  Prion diseases of humans and animals: their causes and molecular basis. , 2001, Annual review of neuroscience.

[7]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[8]  M. Palmer,et al.  Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease , 1991, The Lancet.

[9]  John Collinge,et al.  Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease , 1991, Nature.

[10]  J Collinge,et al.  Molecular neurology of prion disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  S. Mohri,et al.  Human Prion Protein (PrP) 219K Is Converted to PrPSc but Shows Heterozygous Inhibition in Variant Creutzfeldt-Jakob Disease Infection* , 2009, Journal of Biological Chemistry.

[12]  Andrew F. Hill,et al.  The same prion strain causes vCJD and BSE , 1997, Nature.

[13]  S. Cousens,et al.  Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.

[14]  R. Shin,et al.  Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease , 1998, The Lancet.

[15]  J. Collinge,et al.  BSE prions propagate as either variant CJD‐like or sporadic CJD‐like prion strains in transgenic mice expressing human prion protein , 2002, The EMBO journal.

[16]  B. Chesebro,et al.  Strain Specific Resistance to Murine Scrapie Associated with a Naturally Occurring Human Prion Protein Polymorphism at Residue 171 , 2011, PLoS pathogens.

[17]  F. Cohen,et al.  Dominant-negative inhibition of prion replication in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Andrew F. Hill,et al.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD , 1996, Nature.

[19]  J. Collinge,et al.  Review: Contribution of transgenic models to understanding human prion disease , 2010, Neuropathology and applied neurobiology.

[20]  J. Collinge,et al.  Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Collinge,et al.  Crystal structure of human prion protein bound to a therapeutic antibody , 2009, Proceedings of the National Academy of Sciences.

[22]  H. Budka,et al.  Molecular classification of sporadic Creutzfeldt-Jakob disease. , 2003, Brain : a journal of neurology.

[23]  J. Collinge,et al.  Human Prion Protein with Valine 129 Prevents Expression of Variant CJD Phenotype , 2004, Science.

[24]  M. Palmer,et al.  Unaltered susceptibility to BSE in transgenic mice expressing human prion protein , 1995, Nature.

[25]  Claudio J. Verzilli,et al.  A novel protective prion protein variant that colocalizes with kuru exposure. , 2009, The New England journal of medicine.

[26]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[27]  Aaron Derdowski,et al.  Dominant Prion Mutants Induce Curing Through Pathways That Promote Chaperone-Mediated Disaggregation , 2011, Nature Structural &Molecular Biology.

[28]  J. Collinge,et al.  Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins , 2009, The Journal of general virology.

[29]  J. Collinge,et al.  Kuru prions and sporadic Creutzfeldt–Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice , 2008, Proceedings of the National Academy of Sciences.

[30]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.